ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
PTBP1-Mediated Alternative Splicing of DNAJB6 Promotes Everolimus Resistance in Clear Cell Renal Cell Carcinoma via EIF4B/PKIB/AKT/mTOR Positive Feedback Loop.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundEverolimus (EVE) is a key treatment for advanced clear cell renal cell carcinoma (ccRCC), mainly targeting AKT/mTOR signaling. However, developed resistance remains a major challenge for EVE treatment. Aberrant alternative splicing, particularly regulated by PTBP1, may represent a critical mechanism enabling the activation of these resistance-associated pathways.
methodsSingle-cell transcriptome sequencing is performed to reveal the association between PTBP1 expression, EVE resistance and AKT/mTOR pathway activity. Patient-derived specimens, animal models, and in vitro assays are used to evaluate the role of PTBP1 in EVE resistance. Full-length transcriptome sequencing and crosslinking immunoprecipitation (CLIP) sequencing are employed to identify PTBP1-regulated splicing targets. Co-immunoprecipitation, proteomic analyses, and molecular docking further elucidate the mechanism by which DNAJB6b re-activated AKT/mTOR signaling.
resultsPTBP1 is upregulated in EVE-resistant tumors and its expression positively correlates with AKT/mTOR signaling activation. PTBP1 promotes the expression of the DNAJB6b isoform through alternative splicing. EIF4B is identified as a direct binding partner of DNAJB6b, forming a complex that enhances oncogenic translation and activates a PKIB-dependent AKT/mTOR signaling cascade.
conclusionThis study demonstrates that PTBP1 drives EVE resistance in ccRCC by upregulating DNAJB6b, which recruits EIF4B to initiate a PKIB/AKT/mTOR positive feedback loop, sustaining oncogenic translation and therapeutic evasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.